Studies presented at leading ophthalmology and gene therapy conferences demonstrate therapeutic potential in geographic atrophy and wet AMD, leading causes of legal blindness
This single-administration gene therapy approach could replace frequent eye injections for geographic atrophy and wet AMD patients
The lead candidate IKAR-001 (previously known as IKC159V) will proceed to a geographic atrophy clinical trial supported by studies showing preservation of cells critical for vision
Norwich, UK, May 28 2025 – Ikarovec, a leader in ophthalmology innovation with a sophisticated field-…
Sandwich, UK - 28 May 2025: Discovery Park has launched applications for its immersive business growth programme, ‘Discovery Spark’, seeking early-stage companies in cardiovascular and cardiometabolic health.
Partnered with health-specialist venture capital firm Zinc, the initiative offers expert-led business skills sessions and the opportunity to secure £250k Zinc investment.
Discovery Spark is a transformative business programme for early-stage startups, led by science and tech hub Discovery Park. With practical sessions bridging the gap between science and business, Discovery Spark…
Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.
MDC’s Chemical Protein Stability Assay (CPSA) is a distinctive technology used to assess target engagement. It can be applied at every step of the drug discovery process to support drug development, screening, and optimisation.
Target engagement is a key step in early-stage drug discovery. By understanding the relationship between drug/target binding and efficacy, innovators…
Creative Biolabs is dedicated to helping researchers overcome gene therapy delivery research challenges with its wide technical support and services.Gene therapy is highly promising for the treatment of numerous genetic disorders, but there are significant restrictions on its application to effective clinical interventions. Most prominent among these is the development of efficient and safe systems of gene delivery, both viral and non-viral vectors.Creative Biolabs has recently enhanced its technology platform to enable viral vector manufacturing from small to large scales with good titers,…
• Maxion Therapeutics expands its Cambridge headquarters and doubles the size of its offices and laboratory space• Howard Group provides tailored real estate solution to support the biotech’s growthCambridge, 20th May 2025: Leading regional property investor and developer Howard Group, is delighted to announce that pioneering biotechnology company Maxion Therapeutics has more than doubled its footprint at Unity Campus.Following its successful £58 million ($72 million) Series A funding round earlier this year, Maxion has signed a new lease for…
Partnership with SCINCO strengthens international sales and technical support channels in key region as part of ongoing global expansion
Cambridge, UK, 20 May 2025: CN Bio, a leading provider of Organ-on-a-chip (OOC) systems and solutions that accelerate drug discovery and development workflows, today announced a strategic partnership with SCINCO, a specialist scientific instrument company based in South Korea. The agreement is the latest milestone in CN Bio’s international expansion, amplifying the Company’s presence in major Asian and Pacific markets and broadening access to its predictive…
Creative Biolabs is at the forefront of creating stem cell therapy, working with researchers to make new scientific advancements.Induced pluripotent stem cells (iPSCs) contain the unprecedented possibility of differentiating into almost every cell in the body, which holds vast avenues for disease studying and developing novel therapies. Nonetheless, iPSC-based cell therapy is presently problematic. Issues like low reprogramming efficiency, genomic instability, risk of tumorigenicity, and failure in controlling differentiation encompass significant setbacks.Creative Biolabs, a US biotech firm…
Arecor Therapeutics plc
(“Arecor” or the “Company”)
ARECOR ESTABLISHES PARTNERSHIP WITH SKYE BIOSCIENCE TO DEVELOP ENHANCED FORMULATION OF OBESITY CANDIDATE NIMACIMAB
- Proprietary formulation technology being applied to potentially enhance properties of nimacimab
Cambridge, UK, 19th May 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces a formulation development collaboration with Skye Bioscience [Nasdaq: SKYE], a clinical-stage biotechnology company focused on obesity and other metabolic health…
Dozens of pharmaceutical companies and tech start-ups came together on Wednesday (14 May), to celebrate the one-year anniversary of a ‘super hub’ they have used to help accelerate their business.
The Deloitte Life Sciences Catalyst business lounge in Cambridge has helped hundreds of local and regional start-ups across the life sciences industry access a boardroom meeting space and state-of-the-art innovation hub for free.
The space, designed to be a regional hotspot for start-ups and world-leading businesses in the life sciences sector, was opened by Deloitte Cambridge in May 2024…
In an informative original blog - Amsbio reports how researchers at the University of Exeter Medical School have shed light on the role of microRNA - miR-483-5p in attenuating the detrimental effects of stress on brain function and anxiety-related behaviors.
MicroRNAs (miRNAs) are small RNA sequences that regulate gene expression and are implicated in some neuropsychiatric conditions. This published study focuses on miR-383-5p’s regulatory role in the amygdala, a region of the brain involved in emotional processing, known to play a crucial role in…